首页 > 最新文献

Current treatment options in infectious diseases最新文献

英文 中文
The Present and Future State of Antimicrobial Stewardship and Rapid Diagnostic Testing: Can One Ideally Succeed Without the Other? 抗菌素管理和快速诊断测试的现状和未来:两者缺一不可吗?
Pub Date : 2019-06-01 DOI: 10.1007/s40506-019-00190-9
K. Zeitler, Navaneeth Narayanan
{"title":"The Present and Future State of Antimicrobial Stewardship and Rapid Diagnostic Testing: Can One Ideally Succeed Without the Other?","authors":"K. Zeitler, Navaneeth Narayanan","doi":"10.1007/s40506-019-00190-9","DOIUrl":"https://doi.org/10.1007/s40506-019-00190-9","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"11 1","pages":"177-187"},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-019-00190-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48941030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Advances in Infection Control for Clostridioides (Formerly Clostridium) difficile Infection 艰难梭菌感染控制研究进展
Pub Date : 2019-03-01 DOI: 10.1007/s40506-019-0179-y
Carlos E Figueroa Castro, L. Munoz-Price
{"title":"Advances in Infection Control for Clostridioides (Formerly Clostridium) difficile Infection","authors":"Carlos E Figueroa Castro, L. Munoz-Price","doi":"10.1007/s40506-019-0179-y","DOIUrl":"https://doi.org/10.1007/s40506-019-0179-y","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"11 1","pages":"12-22"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-019-0179-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43986564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Procalcitonin as a Diagnostic, Therapeutic, and Prognostic Tool: a Critical Review 降钙素原作为一种诊断、治疗和预后工具:综述
Pub Date : 2019-02-21 DOI: 10.1007/s40506-019-0178-z
Fabricio Rodrigues Torres de Carvalho, Roberto Rabello Filho, Lucas Bulgarelli, A. Serpa Neto, R. Deliberato
{"title":"Procalcitonin as a Diagnostic, Therapeutic, and Prognostic Tool: a Critical Review","authors":"Fabricio Rodrigues Torres de Carvalho, Roberto Rabello Filho, Lucas Bulgarelli, A. Serpa Neto, R. Deliberato","doi":"10.1007/s40506-019-0178-z","DOIUrl":"https://doi.org/10.1007/s40506-019-0178-z","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"11 1","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2019-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-019-0178-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"52813997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovations in Quality Improvement of Intravascular Catheter-Related Bloodstream Infections 血管内导管相关血流感染质量改进的创新
Pub Date : 2019-02-08 DOI: 10.1007/s40506-019-0180-5
Rajendra Karnatak, M. Rupp, Kelly A. Cawcutt
{"title":"Innovations in Quality Improvement of Intravascular Catheter-Related Bloodstream Infections","authors":"Rajendra Karnatak, M. Rupp, Kelly A. Cawcutt","doi":"10.1007/s40506-019-0180-5","DOIUrl":"https://doi.org/10.1007/s40506-019-0180-5","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"11 1","pages":"23-41"},"PeriodicalIF":0.0,"publicationDate":"2019-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-019-0180-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44976584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Tuberculosis in Brazil—Past, Present, and Future Challenges 巴西结核病的治疗——过去、现在和未来的挑战
Pub Date : 2019-01-26 DOI: 10.1007/s40506-019-0182-3
D. Jarovsky
{"title":"Treatment of Tuberculosis in Brazil—Past, Present, and Future Challenges","authors":"D. Jarovsky","doi":"10.1007/s40506-019-0182-3","DOIUrl":"https://doi.org/10.1007/s40506-019-0182-3","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"11 1","pages":"58-72"},"PeriodicalIF":0.0,"publicationDate":"2019-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-019-0182-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47767782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Bacterial Antibiotic Resistance: on the Cusp of a Post-antibiotic World 细菌抗生素耐药性:后抗生素时代的尖端
Pub Date : 2019-01-26 DOI: 10.1007/s40506-019-0181-4
Kameron Sprigg, C. Pietrangeli
{"title":"Bacterial Antibiotic Resistance: on the Cusp of a Post-antibiotic World","authors":"Kameron Sprigg, C. Pietrangeli","doi":"10.1007/s40506-019-0181-4","DOIUrl":"https://doi.org/10.1007/s40506-019-0181-4","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"11 1","pages":"42-57"},"PeriodicalIF":0.0,"publicationDate":"2019-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-019-0181-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44996363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Physician barriers to implementation of hospital-based antimicrobial stewardship programs (ASPs): a global perspective 医生实施医院抗菌药物管理计划的障碍:全球视角
Pub Date : 2019-01-22 DOI: 10.1007/s40506-019-0183-2
L. Kaljee, Tyler Prentiss, M. Zervos
{"title":"Physician barriers to implementation of hospital-based antimicrobial stewardship programs (ASPs): a global perspective","authors":"L. Kaljee, Tyler Prentiss, M. Zervos","doi":"10.1007/s40506-019-0183-2","DOIUrl":"https://doi.org/10.1007/s40506-019-0183-2","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"11 1","pages":"73-80"},"PeriodicalIF":0.0,"publicationDate":"2019-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-019-0183-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43850269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Update on Adverse Effects of HIV Integrase Inhibitors. 艾滋病毒整合酶抑制剂不良反应的最新情况。
Pub Date : 2019-01-01 Epub Date: 2019-11-16 DOI: 10.1007/s40506-019-00203-7
Agnieszka Kolakowska, Anaenza Freire Maresca, Intira Jeannie Collins, Johann Cailhol

Purpose of review: The goal of this paper is to provide an up-to-date review of adverse events related to the class of integrase strand transfer inhibitors (INSTIs), which became the class of choice in few years. We sought answers specifically to issues pertaining to neuropsychiatric adverse events, as well as weight gain, which were the two most important categories of adverse events raised in recent studies based on real-life experience. The primary focus of this paper is on adults with a brief summary on pregnant women and children/adolescents.

Recent findings: Dolutegravir (DTG) bears the heaviest burden of neuropsychiatric side effects. Weight gain was reported with all INSTIs, although there are methodological caveats in the analyses and the findings need to be interpreted with caution.Moreover, due to recent findings on neural tube defects in infants exposed to dolutegravir during their peri-conception period, its use is not recommended for women of childbearing age without proper birth control method, while raltegravir remains the only drug which may be prescribed without caution. Given the importance of cognitive and metabolic co-morbidities in people living with HIV in regard to their quality of life, future research needs to focus on long-term effects of INSTIs in relation to these adverse events. Pharmacogenetics seems to be a promising tool. Safety during pregnancy is also another important issue to further clarify.

Summary: INSTIs are a generally well-tolerated class of antiretrovirals (ARV), and has a higher antiviral potency compared to other classes of ARV.Clinicians and patients need however to be aware of some red flags when starting with and monitoring patients on INSTIs.All INSTIs can lead to mild increases in creatinine levels, usually without clinical significance, but caution is needed in patients with low eGFR (<30ml/min), when using other nephrotoxic drugs, such as as tenofovir disoproxil.Neuro-psychiatric (NP) effects are to be monitored with INSTIs, especially with DTG (though reports are at times contradictory); clinicians might want to avoid DTG for patients with history of severe NP symptoms, until clarity is provided.Weight gain was reported with all INSTIs, especially with DTG, with possible differential effects according to sex and ethnicity (female and non-white patients being at increased risk). This is worrying since patients from African descent are at higher risk of cardio-vascular events and increased body mass index (BMI) can cause further increase metabolic risk. There is possibly an additional effect of tenofovir alafenamide (TAF) on weight increase.Discrepancies between clinical trials - with low rates of adverse events - and reports from real-life settings might be due partly to under-representation of some groups of patients in clinical trials, and/or the short duration of follow-up, since some adverse effects may only occur after prolo

综述目的:本文旨在提供与整合酶链转移抑制剂(INSTIs)类药物相关的不良事件的最新综述,该类药物在几年内成为首选药物。我们特别寻求与神经精神不良事件和体重增加有关的问题的答案,这是近期研究中根据实际生活经验提出的两类最重要的不良事件。本文主要关注成人,并对孕妇和儿童/青少年进行了简要总结:多鲁特拉韦(DTG)的神经精神副作用最为严重。此外,由于最近发现在围孕期接触多曲拉韦的婴儿会出现神经管缺陷,因此不建议未采取适当节育措施的育龄妇女使用多曲拉韦,而拉替拉韦仍然是唯一一种可以慎用的药物。鉴于认知和代谢并发症对艾滋病毒感染者生活质量的重要性,未来的研究需要关注 INSTIs 对这些不良事件的长期影响。药物遗传学似乎是一个很有前途的工具。然而,临床医生和患者在开始使用 INSTIs 并对其进行监测时,需要注意一些警示信号。
{"title":"Update on Adverse Effects of HIV Integrase Inhibitors.","authors":"Agnieszka Kolakowska, Anaenza Freire Maresca, Intira Jeannie Collins, Johann Cailhol","doi":"10.1007/s40506-019-00203-7","DOIUrl":"10.1007/s40506-019-00203-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>The goal of this paper is to provide an up-to-date review of adverse events related to the class of integrase strand transfer inhibitors (INSTIs), which became the class of choice in few years. We sought answers specifically to issues pertaining to neuropsychiatric adverse events, as well as weight gain, which were the two most important categories of adverse events raised in recent studies based on real-life experience. The primary focus of this paper is on adults with a brief summary on pregnant women and children/adolescents.</p><p><strong>Recent findings: </strong>Dolutegravir (DTG) bears the heaviest burden of neuropsychiatric side effects. Weight gain was reported with all INSTIs, although there are methodological caveats in the analyses and the findings need to be interpreted with caution.Moreover, due to recent findings on neural tube defects in infants exposed to dolutegravir during their peri-conception period, its use is not recommended for women of childbearing age without proper birth control method, while raltegravir remains the only drug which may be prescribed without caution. Given the importance of cognitive and metabolic co-morbidities in people living with HIV in regard to their quality of life, future research needs to focus on long-term effects of INSTIs in relation to these adverse events. Pharmacogenetics seems to be a promising tool. Safety during pregnancy is also another important issue to further clarify.</p><p><strong>Summary: </strong>INSTIs are a generally well-tolerated class of antiretrovirals (ARV), and has a higher antiviral potency compared to other classes of ARV.Clinicians and patients need however to be aware of some red flags when starting with and monitoring patients on INSTIs.All INSTIs can lead to mild increases in creatinine levels, usually without clinical significance, but caution is needed in patients with low eGFR (<30ml/min), when using other nephrotoxic drugs, such as as tenofovir disoproxil.Neuro-psychiatric (NP) effects are to be monitored with INSTIs, especially with DTG (though reports are at times contradictory); clinicians might want to avoid DTG for patients with history of severe NP symptoms, until clarity is provided.Weight gain was reported with all INSTIs, especially with DTG, with possible differential effects according to sex and ethnicity (female and non-white patients being at increased risk). This is worrying since patients from African descent are at higher risk of cardio-vascular events and increased body mass index (BMI) can cause further increase metabolic risk. There is possibly an additional effect of tenofovir alafenamide (TAF) on weight increase.Discrepancies between clinical trials - with low rates of adverse events - and reports from real-life settings might be due partly to under-representation of some groups of patients in clinical trials, and/or the short duration of follow-up, since some adverse effects may only occur after prolo","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"11 4","pages":"372-387"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38767623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Challenges in Antibiotic Stewardship in Low- and Middle-Income Countries 当前中低收入国家抗生素管理面临的挑战
Pub Date : 2018-07-17 DOI: 10.1007/s40506-018-0175-7
A. Galindo-Fraga, M. Villanueva-Reza, E. Ochoa-Hein
{"title":"Current Challenges in Antibiotic Stewardship in Low- and Middle-Income Countries","authors":"A. Galindo-Fraga, M. Villanueva-Reza, E. Ochoa-Hein","doi":"10.1007/s40506-018-0175-7","DOIUrl":"https://doi.org/10.1007/s40506-018-0175-7","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"10 1","pages":"421-429"},"PeriodicalIF":0.0,"publicationDate":"2018-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-018-0175-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48920299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Cutaneous Botryomycosis and Staphylococcus aureus: Diagnosis, Management, and a Systemic Literature Review 皮肤芽孢菌病和金黄色葡萄球菌:诊断、管理和系统文献综述
Pub Date : 2018-07-16 DOI: 10.1007/s40506-018-0176-6
Pamela Bailey, Jillian E. Raybould, Sangeeta Sastry, G. Bearman
{"title":"Cutaneous Botryomycosis and Staphylococcus aureus: Diagnosis, Management, and a Systemic Literature Review","authors":"Pamela Bailey, Jillian E. Raybould, Sangeeta Sastry, G. Bearman","doi":"10.1007/s40506-018-0176-6","DOIUrl":"https://doi.org/10.1007/s40506-018-0176-6","url":null,"abstract":"","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"10 1","pages":"347-361"},"PeriodicalIF":0.0,"publicationDate":"2018-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-018-0176-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44202741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Current treatment options in infectious diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1